1625669-67-1

Basic information

• Product Name: 4-(3-(2-(methylsulfonyl)ethyl)-2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-1,2,3,4,5,6,7,8-octahydroquinazolin-4-yl)benzonitrile
• Synonyms: 4-(3-(2-(methylsulfonyl)ethyl)-2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-1,2,3,4,5,6,7,8-octahydroquinazolin-4-yl)benzonitrile
• CAS NO: 1625669-67-1
• Molecular Weight: 517.529
• Mol File: 1625669-67-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(3-(2-(methylsulfonyl)ethyl)-2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-1,2,3,4,5,6,7,8-octahydroquinazolin-4-yl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-(2-(methylsulfonyl)ethyl)-2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-1,2,3,4,5,6,7,8-octahydroquinazolin-4-yl)benzonitrile(1625669-67-1)
• EPA Substance Registry System: 4-(3-(2-(methylsulfonyl)ethyl)-2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-1,2,3,4,5,6,7,8-octahydroquinazolin-4-yl)benzonitrile(1625669-67-1)

Safety Data

• Hazardous Substances Data: 1625669-67-1(Hazardous Substances Data)

Upstream product

• 504-02-9 1,3-cylohexanedione 
• 105-07-7 4-cyanobenzaldehyde 
• 1625672-08-3 1-((4-cyanophenyl)(2-ethoxy-6-oxocyclohex-1-enyl)methyl)-3-(3-(trifluoromethyl)-phenyl)urea 
• 13114-87-9 N-(3-trifluoromethylphenyl)urea 
• 1625672-07-2 1-((4-cyanophenyl)(2-hydroxy-6-oxocyclohex-1-enyl)methyl)-3-(3-(trifluoromethyl)-phenyl)urea 
• 51924-57-3 3-[3-(trifluoromethyl)phenyl]aminocyclohex-2-en-1-one 
• 67280-72-2 1-bromo-4-(chloro(isocyanato)methyl)benzene 
• 1625672-06-1 4-(4-bromophenyl)-1-(3-(trifluoromethyl)phenyl)-3,4,7,8-tetrahydroquinazoline-2,5(1H,6H)-dione 
• 1621272-81-8 4-(chloro(isocyanato)methyl)benzonitrile 
• 1621272-80-7 diethyl (4-cyanophenyl)methylenedicarbamate 
• 16523-02-7 1-bromo-2-(methylsulfonyl)ethane 
• 1625675-73-1 4-(2,5-dioxo-1-(3-(trifluoromethyl)phenyl)-1,2,3,4,5,6,7,8-octahydroquinazolin-4-yl)-benzonitrile 

Relevant articles and documents

Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity

This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.